Literature DB >> 30301637

Large International Validation of ABSIS and PDAI Pemphigus Severity Scores.

Vivien Hébert1, Claire Boulard2, Estelle Houivet3, Sophie Duvert Lehembre4, Luca Borradori5, Rocco Della Torre5, Claudio Feliciani6, Luca Fania7, Giovanna Zambruno8, Diana B Camaioni8, Biago Didona8, Branka Marinovic9, Enno Schmidt10, Nina Schumacher10, Christian Hünefeld11, Stefan Schanz11, Johannes Steffen Kern12, Silke Hofmann12, Anne Charlotte Bouyeure3, Catherine Picard-Dahan13, Catherine Prost-Squarcioni14, Frederic Caux14, Marina Alexandre14, Saskia Ingen-Housz-Oro15, Martine Bagot16, Emmanuelle Tancrede-Bohin16, Jean David Bouaziz16, Nathalie Franck17, Pierre Vabres18, Bruno Labeille19, Marie Aleth Richard20, Emmanuel Delaporte4, Alain Dupuy21, Michel D'Incan22, Gaelle Quereux23, François Skowro24, Carle Paul25, Cristina Bulai Livideanu25, Marie Beylot-Barry26, Marie Sylvie Doutre26, Martine Avenel-Audran27, Christophe Bedane28, Philippe Bernard29, Laurent Machet30, Hervé Maillard31, Denis Jullien32, Sebastien Debarbieux32, Bruno Sassolas33, Laurent Misery33, Claire Abasq33, Olivier Dereure34, Philippe Lagoutte3, Vincent Ferranti2, Victoria P Werth35, Dedee F Murrell36, Michael Hertl37, Jacques Benichou3, Pascal Joly2.   

Abstract

The Pemphigus Disease Area Index (PDAI) and Autoimmune Bullous Skin Disorder Intensity-Score (ABSIS) scores have been proposed to provide an objective measure of pemphigus activity. These scores have been evaluated only on already treated patients mainly with mild to moderate activity. The objective was to assess the interrater reliability of ABSIS and PDAI scores and their correlation with other severity markers in a large international study. Consecutive patients with newly diagnosed pemphigus were enrolled in 31 centers. Severity scores were recorded during a 24-month period by the same two blinded investigators. Serum was collected at each visit for ELISA measurement of anti-desmoglein antibodies. The intraclass correlation coefficient (ICC) and Spearman rank correlation coefficient were calculated. A total of 116 patients with pemphigus vulgaris (n = 84) or pemphigus foliaceus (n = 32) were included. At baseline, the ABSIS and PDAI ICCs were 0.90 (95% confidence interval [CI] = 0.85-0.93), and 0.91(95% CI = 0.87-0.94), respectively. The ICCs for PDAI were higher in moderate and extensive pemphigus (ICC = 0.82, 95% CI = 0.63-0.92 and ICC = 0.80, 95% CI = 0.62-0.90, respectively) than in patients with intermediate (significant) extent (ICC = 0.50, 95% CI = 0.27-0.68). Conversely, the ICCs for ABSIS were lower in patients with moderate extent (ICC = 0.44, 95% CI = 0.004-0.74) than in those with intermediate or extensive forms, (ICC = 0.69, 95% CI = 0.51-0.81 and ICC = 0.75, 95% CI = 0.51-0.88, respectively). During patients' follow-up, the ICCs of both ABSIS and PDAI scores remained higher than 0.70. ABSIS and PDAI skin (r = 0.71 and r = 0.75) but not mucosal (r = 0.32 and r = 0.37) subscores were correlated with the evolution of anti-DSG1 and anti-DSG3 ELISA values, respectively. ABSIS and PDAI scores are robust tools to accurately assess pemphigus activity.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30301637     DOI: 10.1016/j.jid.2018.04.042

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris.

Authors:  Napatra Tovanabutra; Christina E Bax; Rui Feng; Carolyn J Kushner; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-26       Impact factor: 8.551

2.  Assessment of Immune Cell Activation in Pemphigus.

Authors:  Anna Kowalska-Kępczyńska; Mateusz Mleczko; Weronika Domerecka; Dorota Krasowska; Helena Donica
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

3.  FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus.

Authors:  Maud Maho-Vaillant; Magdalena Sips; Marie-Laure Golinski; Gestur Vidarsson; Matthias Goebeler; Johanna Stoevesandt; Zsuzsanna Bata-Csörgő; Bianca Balbino; Peter Verheesen; Pascal Joly; Michael Hertl; Sébastien Calbo
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

4.  Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen.

Authors:  Vivien Hébert; Maud Maho-Vaillant; Marie-Laure Golinski; Marie Petit; Gaëtan Riou; Olivier Boyer; Philippe Musette; Sébastien Calbo; Pascal Joly
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

5.  The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab.

Authors:  Marie-Laure Golinski; Alexandre Lemieux; Maud Maho-Vaillant; Marion Barray; Laurent Drouot; Damien Schapman; Marie Petit; Michael Hertl; Olivier Boyer; Sébastien Calbo; Pascal Joly; Vivien Hébert
Journal:  Front Immunol       Date:  2022-03-15       Impact factor: 7.561

6.  IgG N-Glycosylation from Patients with Pemphigus Treated with Rituximab.

Authors:  Guillaume Font; Marie-Laure Walet-Balieu; Marie Petit; Carole Burel; Maud Maho-Vaillant; Vivien Hébert; Philippe Chan; Manuel Fréret; Olivier Boyer; Pascal Joly; Sébastien Calbo; Muriel Bardor; Marie-Laure Golinski
Journal:  Biomedicines       Date:  2022-07-22

7.  Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in Pemphigus.

Authors:  Rebecca L Krain; Carolyn J Kushner; Meera Tarazi; Rebecca G Gaffney; Andrea C Yeguez; Danielle E Zamalin; David R Pearson; Rui Feng; Aimee S Payne; Victoria P Werth
Journal:  Front Immunol       Date:  2019-11-06       Impact factor: 7.561

8.  Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.

Authors:  Hoorieh Alaeen; Roja Toosi; Hamidreza Mahmoudi; Kamran Balighi; Soheil Tavakolpour; Amir Teimoupour; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2019-06-07

9.  Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.

Authors:  D F Murrell; A Patsatsi; P Stavropoulos; S Baum; T Zeeli; J S Kern; A-V Roussaki-Schulze; R Sinclair; I D Bassukas; D Thomas; A Neale; P Arora; F Caux; V P Werth; S G Gourlay; P Joly
Journal:  Br J Dermatol       Date:  2021-06-15       Impact factor: 9.302

Review 10.  Comparison of Guidelines for Management of Pemphigus: a Review of Systemic Corticosteroids, Rituximab, and Other Immunosuppressive Therapies.

Authors:  Haiqin Zhu; Meng Pan; Wenzhe Zhao; Jingying Wang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-04       Impact factor: 8.667

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.